Spravato - (28mg Nasal Spray; Single use device)

Generic Name	Esketamine Hydrochloride	Innovator	Janssen Pharma
Dosage	28mg Nasal Spray; Single use device	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	SPRAVATO™ is a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist indicated, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression (TRD) in adults.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
*****	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
*****	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events